← Back to patent-cliff list
Inotersen sodium
Tier C — Watch / tradeInotersen sodium
Ionis Pharmaceuticals Inc
Originator
2018
First approval
-
Expiry (public)
$0.04B ▲
Peak sales
核酸药物
Type
Targets：TTR
Brand：Tegsedi
Indications (approved)：转甲状腺素运载蛋白淀粉样变性、淀粉样变
Regional status
US
批准上市
2018-10-05
EU
批准上市
2018-07-05
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Inotersen sodium?
Approved indications include: 转甲状腺素运载蛋白淀粉样变性, 淀粉样变.
When does the Inotersen sodium patent expire?
No public expiry year is available for Inotersen sodium yet; this page updates once verified.
How do I get a quote for Inotersen sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24